Details for Patent: 11,116,721
Which drugs does patent 11,116,721 protect, and when does it expire?
Patent 11,116,721 protects BREO ELLIPTA and is included in one NDA.
Protection for BREO ELLIPTA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has twenty-five patent family members in thirteen countries.
Summary for Patent: 11,116,721
| Title: | Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol |
| Abstract: | Novel pharmaceutical formulations of a beta-2 agonist for inhaled administration via the nose or mouth, and methods of using them are provided. |
| Inventor(s): | Darrell Baker, Mark Bruce, Marian Thomas |
| Assignee: | Glaxo Group Ltd |
| Application Number: | US13/148,982 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 11,116,721 |
|
Patent Claim Types: see list of patent claims | Use; Formulation; |
Drugs Protected by US Patent 11,116,721
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxo Grp Ltd | BREO ELLIPTA | fluticasone furoate; vilanterol trifenatate | POWDER;INHALATION | 204275-003 | May 12, 2023 | RX | Yes | Yes | 11,116,721*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Glaxo Grp Ltd | BREO ELLIPTA | fluticasone furoate; vilanterol trifenatate | POWDER;INHALATION | 204275-001 | May 10, 2013 | RX | Yes | Yes | 11,116,721*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Glaxo Grp Ltd | BREO ELLIPTA | fluticasone furoate; vilanterol trifenatate | POWDER;INHALATION | 204275-002 | Apr 30, 2015 | RX | Yes | Yes | 11,116,721*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 11,116,721
| PCT Information | |||
| PCT Filed | February 26, 2009 | PCT Application Number: | PCT/EP2009/052306 |
| PCT Publication Date: | September 02, 2010 | PCT Publication Number: | WO2010/097115 |
International Family Members for US Patent 11,116,721
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Cyprus | 1121914 | ⤷ Start Trial | |||
| Denmark | 2400950 | ⤷ Start Trial | |||
| Denmark | 3578169 | ⤷ Start Trial | |||
| European Patent Office | 2400950 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
